October 17, 2007 07:15 ET

REMINDER: ORLive Presents: New Developments in Lymphoma Treatments Live Interactive Panel Discussion

Live Webcast: From NewYork-Presbyterian Hospital: October 17, 2007 7:00 PM EDT (23:00 UTC)

NEW YORK, NY--(Marketwire - October 17, 2007) - Panelists from NewYork-Presbyterian Hospital/Columbia University Medical Center and NewYork-Presbyterian Hospital/Weill Cornell Medical Center will discuss the evolving treatment choices for several different kinds of lymphoma.

While standard therapies for B-cell lymphoma and T-cell lymphoma continually evolve, several new developments, including the emergence of a number of new agents, make it necessary to begin to think about how we might integrate these drugs into our conventional standards of care.

These new agents include proteasome inhibitors like bortezomib, histone deacetylase inhibitors like vorinostat, novel BCL2-targeted drugs, new T-cell-active agents like pralatrexate, new-generation thalidomide analogues like lenalidomide, novel monoclonal antibodies and vaccines, and other agents that are still very much in early clinical trials but which show promise. Several of these novel agents have been discovered and developed at NewYork-Presbyterian Hospital.

It is hoped that adding these new agents to existing lymphoma regimens will optimize efficacy and reduce toxicity compared to conventional agents.

The panelists will discuss additional trials that have yet to be completed as they and others endeavor to discern the best schedules and optimal strategies incorporating the new agents. Further research will continue to try to understand how best to tailor specific agents to specific individuals.

The webcast will be presented on Wednesday, October 17, 2007 at 7 PM EDT. Panelists will include:

-- John P. Leonard, M.D., Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and Professor of Medicine at Weill Cornell Medical College; Director of the New York - Cornell Center for Lymphoma and Myeloma, and Director of Clinical Research, Division of Hematology/Oncology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

-- Owen A. O’Connor, M.D., Ph.D., Associate Professor of Medicine, Department of Medicine, Columbia University College of Physicians and Surgeons; Chief of the Lymphoma Service, and Director of the Lymphoid Development and Malignancy Program in the Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital/Columbia University Medical Center.

Visit: now to learn more and view a program preview. VNR:

Contact Information

  • Contact:

    Alex Fraser
    Director of Marketing
    slp3D, Inc / OR-Live™
    860-953-2900 x 214